Repligen (RGEN) News Today $157.07 -5.60 (-3.44%) As of 02:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Repligen (NASDAQ:RGEN) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPSRepligen (NASDAQ:RGEN - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%.February 21 at 10:43 AM | marketbeat.comRepligen (NASDAQ:RGEN) Stock Price Up 8.1% on Strong EarningsRepligen (NASDAQ:RGEN) Trading Up 8.1% Following Strong EarningsFebruary 21 at 10:40 AM | marketbeat.comRepligen (NASDAQ:RGEN) Updates FY 2025 Earnings GuidanceRepligen (NASDAQ:RGEN) updated its FY 2025 earnings guidance. The company provided EPS guidance of 1.670-1.760 for the period, compared to the consensus estimate of 1.710. The company also issued revenue guidance of $685.0 millionillion-$710.0 millionillion, compared to the consensus estimate of $692.8 millionillion.February 21 at 7:56 AM | marketbeat.comRepligen price target raised to $170 from $165 at CanaccordFebruary 21 at 7:38 AM | markets.businessinsider.comRhumbline Advisers Grows Stock Holdings in Repligen Co. (NASDAQ:RGEN)Rhumbline Advisers increased its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 1.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 146,149 shares of the biotechnology company's stock after acquiring aFebruary 21 at 3:32 AM | marketbeat.comRepligen Corp (RGEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...February 21 at 2:10 AM | gurufocus.comRepligen outlines 10-14% non-COVID revenue growth for 2025 driven by CDMO and equipment tractionFebruary 20 at 6:50 PM | msn.comRepligen price target raised to $165 from $160 at JefferiesFebruary 20 at 6:50 PM | markets.businessinsider.comRepligen stock rises on positive Q4 results and 2025 outlookFebruary 20 at 3:15 PM | investing.comRepligen Corporation (RGEN) Q4 2024 Earnings Call TranscriptFebruary 20 at 3:10 PM | seekingalpha.comRepligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 OutlookFebruary 20 at 2:55 PM | benzinga.comHold Rating for Repligen Amid Mixed Performance and Modest Growth ProjectionsFebruary 20 at 2:55 PM | tipranks.comRepligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 OutlookFebruary 20 at 2:00 PM | benzinga.comWhat To Expect From Repligen Corp (RGEN) Q4 2024 EarningsFebruary 20 at 1:50 PM | finance.yahoo.comRepligen's Q4 Slightly Tops ExpectationsFebruary 20 at 11:25 AM | fool.comRepligen Corporation: Repligen Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 20 at 8:49 AM | finanznachrichten.deRepligen reports Q4 adjusted EPS 44c, consensus 41cFebruary 20 at 8:49 AM | markets.businessinsider.comRepligen Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 20 at 8:49 AM | markets.businessinsider.comRepligen (NASDAQ:RGEN) Posts Q4 Sales In Line With EstimatesFebruary 20 at 8:49 AM | finance.yahoo.comRepligen Corporation Reports Fourth Quarter 2024 Revenue of $168 Million and Provides 2025 Financial GuidanceFebruary 20 at 8:01 AM | quiverquant.comRepligen beats bottom-line estimates; initiates FY25 outlookFebruary 20 at 7:39 AM | seekingalpha.comNew York State Common Retirement Fund Grows Stake in Repligen Co. (NASDAQ:RGEN)New York State Common Retirement Fund raised its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 2.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 581,442 shares of the biotechnology company'sFebruary 20 at 4:37 AM | marketbeat.comEarnings To Watch: Repligen (RGEN) Reports Q4 Results TomorrowFebruary 19 at 7:19 PM | msn.comTimesSquare Capital Management LLC Sells 14,635 Shares of Repligen Co. (NASDAQ:RGEN)TimesSquare Capital Management LLC cut its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 5.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 260,992 shares of the biotechnology companyFebruary 19 at 6:37 AM | marketbeat.comRice Hall James & Associates LLC Purchases New Holdings in Repligen Co. (NASDAQ:RGEN)Rice Hall James & Associates LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 15,391 shares of the biotechnology company's stock, valued at approximately $2,215,000. OFebruary 19 at 5:23 AM | marketbeat.comRepligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 80% Above Its Share PriceFebruary 18 at 10:30 AM | finance.yahoo.comRepligen (RGEN) Receives a Buy from Craig-HallumFebruary 18 at 10:30 AM | markets.businessinsider.comVan ECK Associates Corp Buys 3,066 Shares of Repligen Co. (NASDAQ:RGEN)Van ECK Associates Corp grew its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 7.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 42,226 shares of the biotechnology company's stock after acquiring an aFebruary 18 at 3:27 AM | marketbeat.comCongress Asset Management Co. Increases Stock Position in Repligen Co. (NASDAQ:RGEN)Congress Asset Management Co. lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 12.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 116,620 shares of the biotechnology comFebruary 17, 2025 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Sold by Banque Pictet & Cie SABanque Pictet & Cie SA cut its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 8.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,392 shares of the biotechnology company's stock afterFebruary 15, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Acquires 203,011 Shares of Repligen Co. (NASDAQ:RGEN)Allspring Global Investments Holdings LLC lifted its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 79.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 457,065 shares of the biotechFebruary 14, 2025 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Sold by Legato Capital Management LLCLegato Capital Management LLC decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 31.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,940 shares of the biotechnologyFebruary 13, 2025 | marketbeat.com3 Healthcare Stocks Skating on Thin IceFebruary 12, 2025 | msn.comRepligen (RGEN) Gets a Buy from Craig-HallumFebruary 12, 2025 | markets.businessinsider.comRepligen (RGEN) to Release Earnings on WednesdayFebruary 12, 2025 | americanbankingnews.comRepligen (RGEN) Expected to Announce Earnings on WednesdayRepligen (NASDAQ:RGEN) will be releasing earnings before the market opens on Wednesday, February 19, Financial Modeling Prep reports.February 12, 2025 | marketbeat.comRepligen Corp (RGEN) Announces Upcoming Fourth Quarter 2024 Financial Results ReleaseFebruary 11, 2025 | gurufocus.comRepligen to Report Fourth Quarter and Full Year 2024 Financial ResultsFebruary 11, 2025 | globenewswire.comRepligen started at buy by TD Cowen, limited NIH exposure citedFebruary 10, 2025 | seekingalpha.comCowen initiates Repligen stock with Buy rating, $200 targetFebruary 10, 2025 | msn.comWells Fargo Sticks to Their Buy Rating for Repligen (RGEN)February 10, 2025 | markets.businessinsider.com“Top-Tier”Repligen to Outperform Peers Thanks to AI and Low China ExposureFebruary 10, 2025 | tipranks.comRepligen (NASDAQ:RGEN) Now Covered by Analysts at TD CowenTD Cowen initiated coverage on shares of Repligen in a research report on Monday. They set a "buy" rating and a $200.00 target price on the stock.February 10, 2025 | marketbeat.comWCM Investment Management LLC Has $13.96 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)WCM Investment Management LLC lowered its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 2.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 97,086 shares of the biotechnology companyFebruary 10, 2025 | marketbeat.comMirae Asset Global Investments Co. Ltd. Has $2.68 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 46.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,629 shares of the biotFebruary 10, 2025 | marketbeat.comStephens Investment Management Group LLC Purchases 37,057 Shares of Repligen Co. (NASDAQ:RGEN)Stephens Investment Management Group LLC lifted its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 7.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 536,801 shares of the biotechnology company's stock afFebruary 9, 2025 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Repligen Co. (NASDAQ:RGEN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fourteen research firms that are covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and nine have issued aFebruary 6, 2025 | marketbeat.comTrust Point Inc. Sells 2,107 Shares of Repligen Co. (NASDAQ:RGEN)Trust Point Inc. cut its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 26.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,786 shares of the biotechnology company's stock after selling 2,107 shares duringFebruary 5, 2025 | marketbeat.comConestoga Capital Advisors LLC Purchases 6,872 Shares of Repligen Co. (NASDAQ:RGEN)Conestoga Capital Advisors LLC grew its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 947,582 shares of the biotechnology company's stFebruary 3, 2025 | marketbeat.comSG Americas Securities LLC Decreases Position in Repligen Co. (NASDAQ:RGEN)SG Americas Securities LLC decreased its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 47.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,447 shares of the biotechnology company's stock after sFebruary 2, 2025 | marketbeat.com Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Media Mentions By Week RGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGEN News Sentiment▼0.990.60▲Average Medical News Sentiment RGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGEN Articles This Week▼287▲RGEN Articles Average Week Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Biogen News United Therapeutics News Incyte News BioMarin Pharmaceutical News Neurocrine Biosciences News Exelixis News Exact Sciences News Halozyme Therapeutics News Madrigal Pharmaceuticals News Alkermes News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGEN) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
